PSTV 8-K — Smart Summary

Plus Therapeutics, Inc. filed this 8-K on March 12, 2026 to announce that its 2026 Annual Meeting of Stockholders will be held on May 14, 2026, more than 30 days before the anniversary of the 2025 Annual Meeting. Because of this earlier-than-usual scheduling, the Company is providing revised deadlines for stockholder proposals and director nominations, all set at March 22, 2026.

• The information in Item 8.01 of this report is incorporated by reference into Item 5.08 in its entirety.
• This item is triggered because the 2026 Annual Meeting is scheduled more than 30 days before the anniversary of the 2025 Annual Meeting, requiring new nomination deadlines to be disclosed.
• Previously published deadlines for director nominations set forth in the Company's 2025 proxy statement are no longer applicable.
• Stockholders intending to nominate candidates for election as directors must deliver nominations to the Corporate Secretary no later than 5:00 p.m. Eastern Time on Monday, March 22, 2026.
• To comply with universal proxy rules, stockholders intending to solicit proxies in support of director nominees other than the Company's nominees must provide notice under Rule 14a-19 of the Exchange Act no later than March 22, 2026.
• All director nominations must comply with Delaware law, SEC rules and regulations, and the Company's Bylaws.

• On March 11, 2026, the Board of Directors of Plus Therapeutics, Inc. determined the date of the 2026 Annual Meeting of Stockholders.
• The 2026 Annual Meeting is scheduled for Thursday, May 14, 2026, at 9:00 a.m. Eastern Time.
• The meeting will be held virtually by means of remote communication.
• The record date for stockholders entitled to notice of and to vote at the 2026 Annual Meeting is the close of business on March 18, 2026.
• The Company reserves the right to change the record date, and the date, time, and place of the 2026 Annual Meeting prior to the meeting.
• Because the 2026 Annual Meeting is more than 30 days before the anniversary of the 2025 Annual Meeting, prior deadlines stated in the 2025 proxy statement are no longer applicable.
• The Company is providing revised deadlines pursuant to Rule 14a-5(f) and Rule 14a-18 under the Securities Exchange Act of 1934.
• Stockholder proposals submitted pursuant to Rule 14a-8 for inclusion in proxy materials must be received by the Corporate Secretary no later than March 22, 2026, at 6420 Levit Green Boulevard, Suite 310, Houston, Texas 77021.
• Any Rule 14a-8 proposal received after March 22, 2026 will be considered untimely; all such proposals must comply with applicable laws and regulations.
• Stockholders seeking to bring other business before the meeting or nominate director candidates under the Company's Bylaws must also deliver proposals or nominations to the same address no later than 5:00 p.m. Eastern Time on March 22, 2026.
• Stockholders intending to solicit proxies under the universal proxy rules (Rule 14a-19) in support of director nominees other than the Company's nominees must provide the required notice no later than March 22, 2026.